KR102296106B1 - 허혈에 대한 psd-95 억제제와의 조합 요법 - Google Patents

허혈에 대한 psd-95 억제제와의 조합 요법 Download PDF

Info

Publication number
KR102296106B1
KR102296106B1 KR1020207021829A KR20207021829A KR102296106B1 KR 102296106 B1 KR102296106 B1 KR 102296106B1 KR 1020207021829 A KR1020207021829 A KR 1020207021829A KR 20207021829 A KR20207021829 A KR 20207021829A KR 102296106 B1 KR102296106 B1 KR 102296106B1
Authority
KR
South Korea
Prior art keywords
delete delete
stroke
psd
tat
ischemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020207021829A
Other languages
English (en)
Korean (ko)
Other versions
KR20200092437A (ko
Inventor
마이클 타이미안스키
Original Assignee
노노 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노노 인코포레이티드 filed Critical 노노 인코포레이티드
Priority to KR1020217026955A priority Critical patent/KR102425466B1/ko
Publication of KR20200092437A publication Critical patent/KR20200092437A/ko
Application granted granted Critical
Publication of KR102296106B1 publication Critical patent/KR102296106B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Dermatology (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nuclear Medicine (AREA)
KR1020207021829A 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법 Expired - Fee Related KR102296106B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217026955A KR102425466B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161501117P 2011-06-24 2011-06-24
US61/501,117 2011-06-24
US201261617001P 2012-03-28 2012-03-28
US61/617,001 2012-03-28
PCT/IB2012/053178 WO2012176172A2 (en) 2011-06-24 2012-06-23 Combination therapy for ischemia
KR1020197026571A KR102140169B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197026571A Division KR102140169B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217026955A Division KR102425466B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법

Publications (2)

Publication Number Publication Date
KR20200092437A KR20200092437A (ko) 2020-08-03
KR102296106B1 true KR102296106B1 (ko) 2021-08-30

Family

ID=47423033

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020207021829A Expired - Fee Related KR102296106B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법
KR1020197026571A Expired - Fee Related KR102140169B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법
KR1020227025470A Pending KR20220106862A (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법
KR1020147001639A Expired - Fee Related KR102022116B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법
KR1020217026955A Expired - Fee Related KR102425466B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020197026571A Expired - Fee Related KR102140169B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법
KR1020227025470A Pending KR20220106862A (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법
KR1020147001639A Expired - Fee Related KR102022116B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법
KR1020217026955A Expired - Fee Related KR102425466B1 (ko) 2011-06-24 2012-06-23 허혈에 대한 psd-95 억제제와의 조합 요법

Country Status (19)

Country Link
US (3) US10064910B2 (https=)
EP (3) EP2723363B1 (https=)
JP (5) JP6401057B2 (https=)
KR (5) KR102296106B1 (https=)
CN (1) CN103648518B (https=)
AU (1) AU2012274910B2 (https=)
CA (1) CA2839630A1 (https=)
CY (1) CY1121379T1 (https=)
DK (2) DK2723363T3 (https=)
ES (2) ES2912042T3 (https=)
HR (2) HRP20220519T1 (https=)
HU (2) HUE058238T2 (https=)
LT (1) LT2723363T (https=)
PL (2) PL3427748T3 (https=)
PT (2) PT2723363T (https=)
RS (1) RS57798B1 (https=)
SI (1) SI2723363T1 (https=)
SM (1) SMT201800592T1 (https=)
WO (1) WO2012176172A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210109661A (ko) * 2011-06-24 2021-09-06 노노 인코포레이티드 허혈에 대한 psd-95 억제제와의 조합 요법

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2440230T (pt) 2009-06-10 2021-02-03 Nono Inc Regimes de tratamento para tratamento de doenças neurológicas
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
CZ2012476A3 (cs) * 2012-07-12 2014-01-22 Ústav organické chemie a biochemie Akademie věd ČR, v. v. i. Lipidované peptidy jako antiobezitika
WO2015023830A1 (en) * 2013-08-14 2015-02-19 Stc.Unm Treatment and prevention of stroke and other neurological disorders
US20170165317A1 (en) * 2013-11-26 2017-06-15 Trustees Of Dartmouth College Method for mitigating or alleviating synaptic and cognitive deficits
FR3021319B1 (fr) * 2014-05-22 2018-08-31 Sederma Peptides, compositions les comprenant et utilisations notamment cosmetiques
CZ309217B6 (cs) * 2014-05-27 2022-06-01 Ústav Organické Chemie A Biochemie Av Čr, V.V.I. Lipidované peptidy jako neuroprotektiva
CN106661126B (zh) * 2014-05-28 2021-12-10 诺诺公司 TAT-NR2B9c的氯盐
US9526768B2 (en) 2014-11-13 2016-12-27 Jennifer Mai Compositions for the treatment of cancer
CN104497106B (zh) * 2014-12-05 2017-05-10 华中科技大学 一种小分子多肽、其应用及产品
KR102253900B1 (ko) * 2016-04-27 2021-05-18 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경독성 관련 손상 치료용 펩타이드
JP2019522675A (ja) * 2016-04-27 2019-08-15 ▲拝▼西欧斯（北京）生物技▲術▼有限公司 興奮製神経毒性に関連した損傷の治療方法
CN107312069B (zh) * 2016-04-27 2018-11-06 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗肽
CN107446016A (zh) * 2016-05-30 2017-12-08 上海交通大学 一种硬脂酸修饰的细胞穿膜肽及其制备与应用
CN106265594B (zh) * 2016-09-21 2019-07-26 南京医科大学 一种缺血性脑卒中靶向的红细胞膜仿生智能药物载体及其制备方法
CN106749559B (zh) * 2016-11-23 2020-09-04 郑州大学 一种基于细胞穿膜肽Tat(49-57)的抗菌肽及其合成方法
JP7109958B2 (ja) * 2017-04-04 2022-08-01 キヤノンメディカルシステムズ株式会社 磁気共鳴イメージングシステム、磁気共鳴イメージング装置、及び磁気共鳴イメージング方法
BR112020000115A2 (pt) * 2017-07-05 2020-07-07 Biocells (Beijing) Biotech Co., Ltd. sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
WO2019006691A1 (zh) * 2017-07-05 2019-01-10 拜西欧斯（北京）生物技术有限公司 用于治疗、改善或预防脑出血的肽及其用途
JP7073486B2 (ja) * 2017-09-30 2022-05-23 ▲拝▼西欧斯（北京）生物技▲術▼有限公司 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
WO2019195741A1 (en) * 2018-04-06 2019-10-10 Northwestern University Bdnf mimetic peptide amphiphiles
JP7158904B2 (ja) * 2018-06-14 2022-10-24 社会福祉法人 恩賜財団済生会熊本病院 治療方針決定支援装置、治療方針決定支援装置の作動方法、および治療方針決定支援プログラム
US12285182B2 (en) 2018-10-10 2025-04-29 Innova Vascular, Inc. Devices and methods for removing an embolus
JP2023511057A (ja) * 2020-01-09 2023-03-16 ノノ インコーポレイテッド 脳卒中及び関連疾患を治療するためのプラスミン耐性ペプチド
CA3170425A1 (en) * 2020-02-19 2021-08-26 Nono Inc. Inhibition of reperfusion injury with a psd-95 inhibitor
IL295727A (en) * 2020-02-19 2022-10-01 Nono Inc Combined treatment of stroke with a plasmin-degradable and reperfusion psd-95 inhibitor
CN113735938B (zh) * 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
WO2023192848A1 (en) * 2022-03-28 2023-10-05 University Of Maryland, Baltimore Methods and compositions for the treatment of stroke
WO2024149230A1 (zh) 2023-01-09 2024-07-18 北京拓界生物医药科技有限公司 一种神经保护性psd-95多肽抑制剂及其应用
CN117422722B (zh) * 2023-12-19 2024-03-29 北京智源人工智能研究院 基于adc图像的肿瘤预后特征评估的方法和装置

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2742152B1 (fr) 1995-12-06 1998-01-16 Synthelabo Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique
US6562345B1 (en) 1996-11-12 2003-05-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6903184B1 (en) 1998-03-02 2005-06-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multiple antigenic peptides immunogenic against Streptococcus pneumonia
US20060148711A1 (en) 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
GB0025473D0 (en) * 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
AU2004233862A1 (en) 2003-04-25 2004-11-11 Mitos Pharmaceuticals, Inc. Prophylactic pretreatment with antioxidants
EP1622639B1 (de) * 2003-05-02 2013-01-16 Lundbeck, H., A/S Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall
BRPI0410470A (pt) * 2003-05-19 2006-06-20 Kenneth S Warren Inst Inc uso de uma eritropoietina ou de uma citocina protetora de tecido e método para proteger ou manter a viabilidade de uma célula, tecido ou órgão de mamìfero respondente
TWI395591B (zh) 2004-04-01 2013-05-11 Oncothyreon Inc 黏液性糖蛋白（ｍｕｃ-１）疫苗
WO2008008348A2 (en) 2006-07-11 2008-01-17 Arbor Vita Corporation Method and compositions for treating stroke with fever
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
DK2120987T3 (en) * 2007-03-02 2014-02-24 Nono Inc Treatment of stroke and other diseases without inhibiting N-type calcium channels
GB0707348D0 (en) 2007-04-17 2007-05-23 Renovo Ltd Medicaments and methods for inhibition of scarring
WO2009006611A1 (en) 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
CA2701420C (en) 2007-10-29 2016-02-09 Helix Biomedix Inc. Protective skin care tetrapeptides
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
KR101720760B1 (ko) 2008-01-25 2017-03-28 오르후스 우니베르시테트 Ｉｇｆｂｐ-4에 대한 ｐａｐｐ-ａ 활성의 선택적 엑소사이트 억제
WO2010004003A2 (en) 2008-07-09 2010-01-14 University Of Copenhagen Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction
DE102008037564A1 (de) 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
CA2665302A1 (en) 2009-05-01 2010-11-01 Universite De Montreal Cd36 modulation and uses thereof
PT2440230T (pt) 2009-06-10 2021-02-03 Nono Inc Regimes de tratamento para tratamento de doenças neurológicas
CA3018494C (en) 2009-06-10 2021-12-07 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
US20110144029A1 (en) 2009-09-30 2011-06-16 Board Of Regents, The University Of Texas System Model Systems and Materials for the Study and Treatment of Neurodegenerative Diseases
EP2723363B1 (en) 2011-06-24 2018-08-29 NoNO Inc. Combination therapy for ischemia
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
JP6279483B2 (ja) 2011-12-13 2018-02-14 ノノ インコーポレイテッド くも膜下出血および虚血の治療法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The journal of Canadian Journal of Neurological Sciences, Vol 38, (Supplement 1), May 2011*

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210109661A (ko) * 2011-06-24 2021-09-06 노노 인코포레이티드 허혈에 대한 psd-95 억제제와의 조합 요법
KR102425466B1 (ko) * 2011-06-24 2022-07-25 노노 인코포레이티드 허혈에 대한 psd-95 억제제와의 조합 요법

Also Published As

Publication number Publication date
JP6401057B2 (ja) 2018-10-03
WO2012176172A2 (en) 2012-12-27
EP3427748B1 (en) 2022-03-02
AU2012274910B2 (en) 2017-05-11
SI2723363T1 (sl) 2018-12-31
DK2723363T3 (en) 2018-10-15
US20210308209A1 (en) 2021-10-07
US20190091283A1 (en) 2019-03-28
JP2019038831A (ja) 2019-03-14
EP3427748A1 (en) 2019-01-16
JP2022188068A (ja) 2022-12-20
PL2723363T3 (pl) 2018-12-31
US10064910B2 (en) 2018-09-04
HUE058238T2 (hu) 2022-07-28
CN103648518B (zh) 2016-11-16
KR102425466B1 (ko) 2022-07-25
US11878044B2 (en) 2024-01-23
SMT201800592T1 (it) 2019-01-11
US20140248257A1 (en) 2014-09-04
RS57798B1 (sr) 2018-12-31
JP2017193535A (ja) 2017-10-26
KR20140053971A (ko) 2014-05-08
AU2012274910A1 (en) 2014-01-16
US10967041B2 (en) 2021-04-06
WO2012176172A3 (en) 2013-03-28
JP7143374B2 (ja) 2022-09-28
KR20210109661A (ko) 2021-09-06
CN103648518A (zh) 2014-03-19
JP2020189859A (ja) 2020-11-26
KR102022116B1 (ko) 2019-09-18
ES2912042T3 (es) 2022-05-24
HRP20181526T1 (hr) 2018-12-14
LT2723363T (lt) 2018-10-25
JP2014520142A (ja) 2014-08-21
KR102140169B1 (ko) 2020-07-31
PT3427748T (pt) 2022-05-03
HRP20220519T1 (hr) 2022-05-27
CA2839630A1 (en) 2012-12-27
KR20220106862A (ko) 2022-07-29
DK3427748T3 (da) 2022-04-19
KR20190107195A (ko) 2019-09-18
HUE040564T2 (hu) 2019-03-28
CY1121379T1 (el) 2020-05-29
KR20200092437A (ko) 2020-08-03
EP2723363A4 (en) 2014-12-10
EP4052721A1 (en) 2022-09-07
PL3427748T3 (pl) 2022-05-30
PT2723363T (pt) 2018-11-08
EP2723363B1 (en) 2018-08-29
ES2690994T3 (es) 2018-11-23
JP7085457B2 (ja) 2022-06-16
EP2723363A2 (en) 2014-04-30

Similar Documents

Publication Publication Date Title
KR102296106B1 (ko) 허혈에 대한 psd-95 억제제와의 조합 요법
US10300110B2 (en) Therapy for subarachnoid hemorrhage and ischemia
KR102114490B1 (ko) 지주막하 출혈 및 허혈에 대한 치료법
HK40003366B (en) Combination therapy for ischemia
HK40003366A (en) Combination therapy for ischemia

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240826

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240826